--- title: "Composite Endpoint, Definition | MedTech Terms" description: "Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke). Plain-English Clinical & Trials definition for MedTech teams, with exa" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/composite-endpoint#term", "name": "Composite Endpoint", "description": "Composite endpoints increase event rates and statistical power but require careful component selection, individually adjudicated definitions, and reporting of component breakdowns to avoid overstating treatment effect.", "url": "https://medtechterms.com/terms/composite-endpoint", "termCode": "composite-endpoint", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/composite-endpoint#article", "headline": "Composite Endpoint", "description": "Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke).", "url": "https://medtechterms.com/terms/composite-endpoint", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/composite-endpoint" }, "about": { "@id": "https://medtechterms.com/terms/composite-endpoint#term" }, "articleSection": "Clinical & Trials", "inLanguage": "en", "keywords": "Composite Endpoint, Clinical & Trials, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "FDA Composite Endpoints Guidance", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents", "publisher": { "@type": "Organization", "name": "FDA" } }, { "@type": "CreativeWork", "name": "FDA - Clinical Trials and Human Subject Protection", "url": "https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection", "publisher": { "@type": "Organization", "name": "FDA" } }, { "@type": "CreativeWork", "name": "ClinicalTrials.gov", "url": "https://clinicaltrials.gov/", "publisher": { "@type": "Organization", "name": "NIH" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/mcid#term", "name": "Minimal Clinically Important Difference", "alternateName": "MCID", "url": "https://medtechterms.com/terms/mcid" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pivotal-trial#term", "name": "Pivotal Trial", "url": "https://medtechterms.com/terms/pivotal-trial" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Clinical & Trials", "item": "https://medtechterms.com/terms?cat=Clinical%20%26%20Trials" }, { "@type": "ListItem", "position": 4, "name": "Composite Endpoint", "item": "https://medtechterms.com/terms/composite-endpoint" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/composite-endpoint#faq", "mainEntity": [ { "@type": "Question", "name": "Why are composite endpoints used in MedTech clinical trials?", "acceptedAnswer": { "@type": "Answer", "text": "Composite endpoints are primarily used to increase the event rate and statistical power of a study, allowing for smaller sample sizes or shorter trial durations. This efficiency is particularly valuable in MedTech, where certain individual clinical events may be rare." } }, { "@type": "Question", "name": "What are the key considerations when designing a composite endpoint?", "acceptedAnswer": { "@type": "Answer", "text": "Key considerations include selecting clinically relevant and ethically sound components, ensuring consistent definitions and adjudication processes for each component, and developing a robust statistical analysis plan that accounts for individual component contributions and potential outcome heterogeneity." } }, { "@type": "Question", "name": "How do regulatory bodies view the reporting of composite endpoints?", "acceptedAnswer": { "@type": "Answer", "text": "Regulatory bodies expect comprehensive reporting of composite endpoints, including detailed breakdowns of individual component events. This transparency allows for a thorough evaluation of the treatment effect and helps avoid overstating clinical benefits based solely on the composite outcome." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Clinical & Trials](/terms?cat=Clinical%20%26%20Trials) 6. / 7. Composite Endpoint [All terms](/terms) Clinical & Trials [Clinical Evidence](/ecosystems/clinical-evidence) # Composite Endpoint Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke). Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Composite endpoints increase event rates and statistical power but require careful component selection, individually adjudicated definitions, and reporting of component breakdowns to avoid overstating treatment effect. What the regulation says Regulators like FDA and EMA acknowledge composite endpoints for their efficiency in clinical trials, particularly for MedTech. However, they emphasize the need for clear justification of component selection, robust statistical analysis plans, and transparency in reporting individual component outcomes to ensure the integrity and interpretability of trial results, as highlighted in FDA guidance documents on clinical trial design. The EU [MDR](/terms/mdr-reporting) also implicitly requires clear, objective, and statistically sound clinical evidence, which applies to the use of composite endpoints. ## What this means in practice Standard practice in cardiovascular device trials (MACE, MALE, NACE); FDA reviewers focus on whether benefit is consistent across components. ## Examples - A cardiovascular device trial uses a composite endpoint of cardiovascular death, non-fatal myocardial infarction, and re-hospitalization for heart failure. Each component is defined according to consensus guidelines and adjudicated by an independent clinical events committee. - A clinical study for a new orthopedic implant uses a composite endpoint comprising revision surgery, significant pain reduction, and functional improvement, with pre-specified criteria for each outcome. The statistical analysis explicitly outlines how each component contributes to the overall result. - In a diabetes management device trial, a composite endpoint might include HbA1c reduction, absence of severe hypoglycemic events, and improved quality of life metrics, with each element meticulously defined and measured. Common pitfalls - • A common pitfall is including components with widely disparate clinical importance, which can obscure a treatment's true effect on patients. Another mistake is failing to pre-specify the hierarchy of components or how missing data for individual components will be handled. Over-interpreting a positive composite endpoint result without examining the contributions of each component can lead to misleading conclusions and regulatory scrutiny. - • Failing to define each component precisely and adjudicate them consistently across all study sites can introduce bias. - • Selecting components that are not causally linked to the disease or treatment mechanism can weaken the validity of the composite endpoint. - • Not adequately powering the study to detect a meaningful difference in the primary, most clinically relevant component, even if the composite endpoint shows significance, is a frequent error. ## Frequently asked questions Why are composite endpoints used in MedTech clinical trials? Composite endpoints are primarily used to increase the event rate and statistical power of a study, allowing for smaller sample sizes or shorter trial durations. This efficiency is particularly valuable in MedTech, where certain individual clinical events may be rare. What are the key considerations when designing a composite endpoint? How do regulatory bodies view the reporting of composite endpoints? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Clinical & Trials Minimal Clinically Important Difference(MCID) Smallest change in a measurement that patients perceive as clinically meaningful. ](/terms/mcid)[ Clinical & Trials Pivotal Trial Definitive clinical study designed to establish safety and effectiveness for marketing authorization. ](/terms/pivotal-trial) ### More in Clinical & Trials · Same category [ Clinical & Trials Adaptive Trial Design Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data. ](/terms/adaptive-trial)[ Clinical & Trials Adverse Event(AE) Any untoward medical occurrence in a subject, whether or not related to the device. ](/terms/adverse-event)[ Clinical & Trials ALCOA+ Data integrity principles: Attributable, Legible, Contemporaneous, Original, Accurate (plus Complete, Consistent, Enduring, Available). ](/terms/alcoa-plus)[ Clinical & Trials Analytical Sensitivity An IVD's ability to detect small quantities of an analyte. ](/terms/analytical-sensitivity) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Clinical Evidence](/ecosystems/clinical-evidence) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 FDA· 2 NIH· 1 1. [1 FDA Composite Endpoints Guidance Verified FDA · fda.gov ](https://www.fda.gov/regulatory-information/search-fda-guidance-documents) 2. [2 FDA - Clinical Trials and Human Subject Protection Verified FDA · fda.gov ](https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection) 3. [3 ClinicalTrials.gov Verified NIH · clinicaltrials.gov ](https://clinicaltrials.gov/) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Clinical evidence intersecting with device security? We support clinical-stage MedTech teams whose investigational devices touch patient data or hospital networks. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Clinical & Trials Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=composite-endpoint) Learn in 60 seconds Card Lesson Quiz Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke). - · Standard practice in cardiovascular device trials (MACE, MALE, NACE); FDA reviewers focus on whether benefit is consistent across components. Remember this Watch out: A common pitfall is including components with widely disparate clinical importance, which can obscure a treatment's true effect on patients. Another mistake is failing to pre-specify the hierarchy of components or how missing data for individual components will be handled. Over-interpreting a positive composite endpoint result without examining the contributions of each component can lead to misleading conclusions and regulatory scrutiny. Related terms - [Minimal Clinically Important Difference(MCID) ](/terms/mcid) - [Pivotal Trial ](/terms/pivotal-trial) You may also need Auto-suggested from Clinical & Trials and shared keywords. - [Sample Size and Statistical Power ](/terms/sample-size-power) - [Primary and Secondary Endpoints ](/terms/primary-secondary-endpoint) - [Master Protocol (Basket / Umbrella / Platform) ](/terms/master-protocol) - [Surrogate Endpoint ](/terms/surrogate-endpoint) - [Unanticipated Adverse Device Effect(UADE) ](/terms/uade) - [Clinical Investigation Plan(CIP) ](/terms/cip) [All Clinical & Trials terms](/terms?cat=Clinical%20%26%20Trials) From the Blue Goat network Related resources and services on this topic. - [ MedTech Launchpad MedTech funding rounds, accelerators, and launch resources. ](https://medtechlaunchguide.com) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)